Hatteras Venture Partners related stories
All articles and analysis
MedImmune Ventures leads Series A round for G1 TherapeuticsG1 Therapeutics said Wednesday that it has closed $12.5 million in Series A financing. MedImmune Ventures led the round with participation from Hatteras Venture Partners and Mountain Group Capital. Also, Dr. Michael Gutch, managing director at MedImmune Ventures and Dr. Ron Laufer, senior managing director at MedImmune Ventures, have joined G1's board of directors. Based in Chapel Hill, NC, G1 is a pharmaceutical company focused on cancer therapy and biodefense applications.
- VC-Backed TetraLogic Pharmaceuticals Names New Leadership Team
TetraLogic Pharmaceuticals said Monday that it has made changes in its leadership team. J. Kevin Buchi has been named president and CEO while Pete A Meyers and Lesley Russell have taken over as CFO and COO respectively. Buchi will be replacing John M. Gill, who will continue to serve on TetraLogic's board of directors. Based in Malvern, Penn., TetraLogic is a biopharmeceutical company. It is backed by Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures and Kammerer Associates.
- VC-Backed Clinipace Worldwide Names New CFO
Clinipace Worldwide said Tuesday that it named Mark Ubert as CFO. In this role, Ubert leads all aspects of the company’s financial operations including accounting, financial reporting, treasury and tax teams. Backed by NXT Capital, Morgan Stanley Expansion Capital, Hatteras Venture Partners, Brooke Private Equity, Osage Venture Partners and Mario Family Partners, Clinipace is a digital contract research organization in Morrisville, North Carolina.
- NXT Capital Backs Clinipace Worldwide's Acquisition of Paragon Biomedical
NXT Capital’s venture finance group has provided financing to support Clinipace Worldwide’s acquisition of Paragon Biomedical. Digital contract research organization Clinipace is headquartered in Morrisville, North Carolina and is backed by Morgan Stanley Expansion Capital, Hatteras Venture Partners, Brooke Private Equity, Osage Venture Partners and Mario Family Partners.
- Lack of Exits Impacts Q3 Fundraising
A total of 52 U.S.-based venture funds raised $1.7B in the quarter, the smallest amount in eight years
- Clinipace Worldwide Seals $15M
Clinipace Worldwide, a digital clinical research organization, has raised $15 million in Series C financing. Morgan Stanley Expansion Capital led the round, which included participation from Durham, N.C.-based Hatteras Venture Partners, and Boston-based Brook Private Equity Advisors. The company will use the money to expand its contract research services. The company is based in Research Triangle Park, N.C.